NASDAQ$ZYXIQ

Zynex Inc · Q3 2023 earnings

Q3 2023 earnings · · Investor relations

Briefing

Zynex's third quarter results were released, demonstrating revenue growth and profitability.

Zynex reported a 20% increase in revenue to $49.9 million and EPS of $0.10 for Q3 2023. The company achieved record-high order numbers and positive cash flow, driven by its pain management division. They also introduced three new therapy products and are developing the next generation of patient monitoring equipment.

  • Q3 2023 revenue increased 20% year-over-year to $49.9 million.
  • Net income reached $3.6 million, with a diluted EPS of $0.10.
  • Orders increased 39% year-over-year, marking the highest number of orders in Company history for the 6th consecutive quarter.
  • Cash from operations was $8.9 million in the third quarter, the highest in Company history.

Headline financials

Total Revenue

$49.9M

Previous: $41.5M+20.2%
EPS (adj)

$0.10

Previous: $0.13-23.1%
Adjusted EBITDA

$7.29M

No prior period
Capital Expenditures

-$630K

Previous: -$332K-89.8%
Free Cash Flow

$10.9M

Previous: $8.66M+26.3%
Net Income

$3.59M

Previous: $4.87M-26.2%
Operating Income

$5.49M

Previous: $6.56M-16.4%
Gross Profit

$40.4M

Previous: $33.1M+21.8%
Cash & Equivalents

$42.5M

Previous: $23.5M+80.7%
Total Assets

$151M

Previous: $115M+31.2%
Stock-Based Comp

$654K

Previous: $578K+13.1%

Revenue & EPS history

Zynex · Revenue · Quarterly

$49.9M

Q3 2023+20.2%vs Q3 2022
Beat estimate in 7 of 16 quarters(44%)
ActualEstimate

Revenue by segment

Zynex · $49.9M total across 2 segments · Q3 2023

  • Supplies
    $33.1M
  • Devices
    $16.9M

Forward guidance

Zynex estimates fourth quarter 2023 revenue to be $52.5-$57.5 million, and diluted EPS to be $0.17-$0.22. 2023 estimates are revenue of $189.5-$194.5 million and Diluted EPS of $0.40-$0.45 per share.

Tailwinds

  • Fourth quarter 2023 revenue is estimated to be $52.5-$57.5 million, an increase of approximately 13% from Q4 2022.
  • Fourth quarter Diluted EPS is estimated to be $0.17-$0.22.
  • 2023 revenue is estimated to be $189.5-$194.5 million.
  • 2023 Diluted EPS is estimated to be $0.40-$0.45 per share.

Headwinds

  • Diluted EPS is impacted by increased operating expenses to support ZMS.
  • Diluted EPS is impacted as the Laser-based Pulse Oximetry products are prepared for FDA submission.
  • Diluted EPS is impacted as the fluid monitor is readied for the market.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 18 quarterly earnings reports · overlaid with Q3 2023

Historical avgQ3 2023

+0.4%

Avg return

Earnings day

-1.8%

Avg return

5 days after

-6.5%

Avg return

30 days after

46%

29 / 63 earnings

Positive

+38.5%

Q3 2014

Best reaction

-51.6%

Q1 2010

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q4 2024-51.3%
Q3 2025+0.0%+0.0%-98.2%
Q2 2025+0.0%+0.0%+0.0%
Q1 2025-25.6%+0.0%+0.0%
Q3 2024+9.1%+0.0%+0.0%
Q2 2024-11.4%+0.0%+0.0%
Q1 2024+2.8%+0.0%+0.0%
Q4 2023-8.8%+0.0%+0.0%
Q3 2023+17.5%+0.0%+0.0%
Q2 2023+3.3%+0.0%+0.0%
Q1 2023+2.5%+0.0%+0.0%
Q4 2022+16.7%+0.0%+0.0%
Q3 2022+15.0%+0.0%+0.0%
Q2 2022+13.3%+0.0%+0.0%
Q1 2022-8.6%+0.0%+0.0%
Q4 2021-1.7%+0.0%+0.0%
Q3 2021+10.0%+0.0%+0.0%
Q2 2021-19.3%+0.0%+0.0%
Q1 2021-9.2%-12.0%-6.3%
Q4 2020-21.2%-22.4%-18.8%
Q3 2020-6.5%
Q2 2020-6.0%
Q1 2020-1.1%
Q4 2019+3.1%
Q3 2019-7.9%
Q2 2019+9.8%
Q1 2019+7.9%
Q4 2018-11.1%
Q3 2018+3.4%
Q2 2018-3.3%
Q1 2018+4.5%
Q4 2017-20.7%
Q3 2017+6.6%
Q2 2017+34.6%
Q1 2017-5.6%
Q4 2016+9.7%
Q3 2016+23.1%
Q2 2016+34.8%
Q1 2016+0.0%
Q4 2015+0.0%
Q3 2015-4.3%
Q2 2015-5.4%
Q4 2014+0.0%
Q1 2015+0.0%
Q3 2014+38.5%
Q2 2014+2.2%
Q1 2014-0.2%
Q4 2013-3.6%
Q3 2013+13.6%
Q2 2013+7.1%
Q1 2013+0.0%
Q4 2012+3.4%
Q3 2012+5.6%
Q2 2012-5.1%
Q1 2012-6.3%
Q4 2011+0.0%
Q3 2010+12.9%
Q3 2011+12.9%
Q2 2011+1.1%
Q1 2011-8.2%
Q4 2010+0.0%
Q2 2010+2.0%
Q1 2010-51.6%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro